Clinical trial results:
A randomized, double-blind, phase III study, comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus (vs.) placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) - daNIS-2

Summary

EudraCT number	2021-000591-10
Trial protocol	HU DE BE ES SK FR SE FI IT NO NL
Global end of trial date	13 August 2024

Results information

Result version number	v1
This version publication date	27 August 2025
First version publication date	27 August 2025

Trial information

Trial identification

Sponsor protocol code	CNIS793B12301

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04935359
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Novartis Pharma AG
Sponsor organisation address	Lichtstrasse 35, Basel, Switzerland, 4056
Public contact	Clinical Disclosure Office, Novartis Pharma AG, 41 613241111, Novartis.email@Novartis.com
Scientific contact	Clinical Disclosure Office, Novartis Pharma AG, 41 613241111, Novartis.email@Novartis.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	13 August 2024
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	13 August 2024
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The purpose of this study was to evaluate the efficacy and safety of NIS793 in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel and placebo in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC). This study aimed to explore whether blockade of Transforming Growth Factor β (TGFβ) in combination with gemcitabine/nab-paclitaxel could reduce fibrosis in PDAC, restore chemo-sensitivity and ultimately lead to improvements in overall survival (OS) and other clinically relevant outcomes.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. All the local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	30 September 2021
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 9
Country: Number of subjects enrolled	Belgium: 18
Country: Number of subjects enrolled	Brazil: 14
Country: Number of subjects enrolled	Canada: 10
Country: Number of subjects enrolled	China: 78
Country: Number of subjects enrolled	Czechia: 18
Country: Number of subjects enrolled	Finland: 3
Country: Number of subjects enrolled	France: 24
Country: Number of subjects enrolled	Germany: 35
Country: Number of subjects enrolled	United Kingdom: 27
Country: Number of subjects enrolled	Greece: 5
Country: Number of subjects enrolled	Hungary: 15
Country: Number of subjects enrolled	Israel: 10
Country: Number of subjects enrolled	Italy: 15
Country: Number of subjects enrolled	Japan: 53
Country: Number of subjects enrolled	Korea, Republic of: 19
Country: Number of subjects enrolled	Netherlands: 2

Country: Number of subjects enrolled	Norway: 4
Country: Number of subjects enrolled	Russian Federation: 3
Country: Number of subjects enrolled	Singapore: 2
Country: Number of subjects enrolled	Slovakia: 7
Country: Number of subjects enrolled	Spain: 23
Country: Number of subjects enrolled	Sweden: 3
Country: Number of subjects enrolled	Switzerland: 9
Country: Number of subjects enrolled	Taiwan: 14
Country: Number of subjects enrolled	Türkiye: 23
Country: Number of subjects enrolled	United States: 68
Worldwide total number of subjects	511
EEA total number of subjects	172

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	268
From 65 to 84 years	243
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

The study was conducted globally across 27 countries.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	Safety run-in: NIS793 + Gem/Nab-paclitaxel combo

Arm description:

Participants received a combination of NIS793, Gemcitabine and Nab-paclitaxel : • NIS793 at 2100 mg (Days 1 and 15) • Gemcitabine at 1000 mg/m² (Days 1, 8 and 15) • Nab-paclitaxel at 125 mg/m² (Days 1, 8 and 15)

Arm type	Experimental
Investigational medicinal product name	NIS793
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

2100 mg (Days 1 and 15)

Investigational medicinal product name	Nab-paclitaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

125 mg/m² (Days 1, 8 and 15)

Investigational medicinal product name	Gemcitabine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

1000 mg/m² (Days 1, 8 and 15)

Arm title	Randomized part (Arm A): NIS793 + Gem/Nab-paclitaxel

Arm description:

Participants received a combination of NIS793, Gemcitabine and Nab-paclitaxel: • NIS793 at 2100 mg (Days 1 and 15) • Gemcitabine at 1000 mg/m² (Days 1, 8 and 15) • Nab-paclitaxel at 125 mg/m² (Days 1, 8 and 15)

Arm type	Experimental

Investigational medicinal product name	NIS793
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

2100 mg (Days 1 and 15) assuming this was the confirmed RP3D in the safety run-in part or NIS793 at 2100 mg on Day 1 if dose level -1 was the confirmed RP3D in the safety run-in

Investigational medicinal product name	Nab-paclitaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

125 mg/m² (Days 1, 8 and 15)

Investigational medicinal product name	Gemcitabine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

1000 mg/m² (Days 1, 8 and 15)

Arm title	Randomized part (Arm B): Placebo + Gem/Nab-paclitaxel

Arm description:

Participants received a combination of placebo, gemcitabine and nab-paclitaxel: • Placebo for NIS793 (Days 1 and 15) • Gemcitabine at 1000 mg/m² (Days 1, 8 and 15) • Nab-paclitaxel at 125 mg/m² (Days 1, 8 and 15)

Arm type	Placebo
Investigational medicinal product name	Gemcitabine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

1000 mg/m² (Days 1, 8 and 15)

Investigational medicinal product name	Placebo for NIS793
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Dextrose 5% in water (D5W) Days 1 and 15

Investigational medicinal product name	Nab-paclitaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

125 mg/m² (Days 1, 8 and 15)

Number of subjects in period 1	Safety run-in: NIS793 + Gem/Nab-paclitaxel combo	Randomized part (Arm A): NIS793 + Gem/Nab-paclitaxel	Randomized part (Arm B): Placebo + Gem/Nab-paclitaxel
Started	21	245	245
Entered post treatment follow-up	18	192	200
Completed	0	0	0
Not completed	21	245	245
Adverse event, serious fatal	-	16	8
Physician decision	2	20	24
Participant decision	-	25	24
Adverse event, non-fatal	1	25	24
Participants not treated due to Protocol deviation	-	1	-
Progressive disease	17	148	149
Lost to follow-up	1	-	-
Sponsor decision	-	9	16
Guardian decision	-	1	-

Baseline characteristics

Reporting groups	
Reporting group title	Safety run-in: NIS793 + Gem/Nab-paclitaxel combo
Reporting group description:	
Participants received a combination of NIS793, Gemcitabine and Nab-paclitaxel : • NIS793 at 2100 mg (Days 1 and 15) • Gemcitabine at 1000 mg/m² (Days 1, 8 and 15) • Nab-paclitaxel at 125 mg/m² (Days 1, 8 and 15)	
Reporting group title	Randomized part (Arm A): NIS793 + Gem/Nab-paclitaxel
Reporting group description:	
Participants received a combination of NIS793, Gemcitabine and Nab-paclitaxel: • NIS793 at 2100 mg (Days 1 and 15) • Gemcitabine at 1000 mg/m² (Days 1, 8 and 15) • Nab-paclitaxel at 125 mg/m² (Days 1, 8 and 15)	
Reporting group title	Randomized part (Arm B): Placebo + Gem/Nab-paclitaxel
Reporting group description:	
Participants received a combination of placebo, gemcitabine and nab-paclitaxel: • Placebo for NIS793 (Days 1 and 15) • Gemcitabine at 1000 mg/m² (Days 1, 8 and 15) • Nab-paclitaxel at 125 mg/m² (Days 1, 8 and 15)	

Reporting group values	Safety run-in: NIS793 + Gem/Nab-paclitaxel combo	Randomized part (Arm A): NIS793 + Gem/Nab-paclitaxel	Randomized part (Arm B): Placebo + Gem/Nab-paclitaxel
Number of subjects	21	245	245
Age Categorical Units: Participants			
<= 65 years	13	130	125
Between 65 and 75 years	7	97	91
>= 75 years	1	18	29
Sex: Female, Male Units: Participants			
Female	6	109	99
Male	15	136	146
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0	3	0
Asian	2	87	87
Native Hawaiian or Other Pacific Islander	0	1	0
Black or African American	0	9	6
White	19	137	143
More than one race	0	1	0
Unknown or Not Reported	0	7	9

Reporting group values	Total		
Number of subjects	511		
Age Categorical Units: Participants			
<= 65 years	268		
Between 65 and 75 years	195		
>= 75 years	48		

Sex: Female, Male Units: Participants			
Female	214		
Male	297		
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	3		
Asian	176		
Native Hawaiian or Other Pacific Islander	1		
Black or African American	15		
White	299		
More than one race	1		
Unknown or Not Reported	16		

End points

End points reporting groups

Reporting group title	Safety run-in: NIS793 + Gem/Nab-paclitaxel combo
Reporting group description:	
Participants received a combination of NIS793, Gemcitabine and Nab-paclitaxel : • NIS793 at 2100 mg (Days 1 and 15) • Gemcitabine at 1000 mg/m² (Days 1, 8 and 15) • Nab-paclitaxel at 125 mg/m² (Days 1, 8 and 15)	
Reporting group title	Randomized part (Arm A): NIS793 + Gem/Nab-paclitaxel
Reporting group description:	
Participants received a combination of NIS793, Gemcitabine and Nab-paclitaxel: • NIS793 at 2100 mg (Days 1 and 15) • Gemcitabine at 1000 mg/m² (Days 1, 8 and 15) • Nab-paclitaxel at 125 mg/m² (Days 1, 8 and 15)	
Reporting group title	Randomized part (Arm B): Placebo + Gem/Nab-paclitaxel
Reporting group description:	
Participants received a combination of placebo, gemcitabine and nab-paclitaxel: • Placebo for NIS793 (Days 1 and 15) • Gemcitabine at 1000 mg/m² (Days 1, 8 and 15) • Nab-paclitaxel at 125 mg/m² (Days 1, 8 and 15)	

Primary: Safety run-in part: Percentage of participants with dose limiting toxicities (DLTs) during the first cycle (4 weeks) of treatment.

End point title	Safety run-in part: Percentage of participants with dose limiting toxicities (DLTs) during the first cycle (4 weeks) of treatment.[1][2]
End point description:	
A dose-limiting toxicity (DLT) was defined as an adverse event or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurred within the first cycle (i.e., 28 days or 4 weeks) of the treatment with NIS793 in combination with gemcitabine/nab-paclitaxel. The National Cancer Institute Common Terminology Criteria for Adverse events (NCI CTCAE) version 5 was used for all grading.	
End point type	Primary
End point timeframe:	
Up to 4 weeks	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only descriptive statistics performed

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Endpoint only applicable to Safety run-in: NIS793 + Gem/Nab-paclitaxel combo Arm

End point values	Safety run-in: NIS793 + Gem/Nab-paclitaxel combo			
Subject group type	Reporting group			
Number of subjects analysed	18			
Units: Participants	0			

Statistical analyses

No statistical analyses for this end point

Primary: Randomized part: Overall Survival (OS)

End point title	Randomized part: Overall Survival (OS)[3][4]

End point description:

Overall Survival (OS) was defined as the time from date of randomization/start of treatment to date of death due to any cause. If a patient was not known to have died, survival was censored at the date of last known date patient alive.

End point type	Primary

End point timeframe:

From randomization up to death, assessed up to approximately 34 months

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only descriptive statistics performed

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Endpoint only applicable to Randomized part Arms A and B

End point values	Randomized part (Arm A): NIS793 + Gem/Nab-paclitaxel	Randomized part (Arm B): Placebo + Gem/Nab-paclitaxel		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	245	245		
Units: Months				
median (confidence interval 95%)	9.2 (8.1 to 10.5)	11.2 (9.6 to 12.1)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants with Adverse Events (AEs)

End point title	Percentage of participants with Adverse Events (AEs)

End point description:

An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a clinical investigation participant after providing written informed consent for participation in the study. Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product.

Treatment emergent Adverse Event (TEAEs) in this study are events that started after the first dose of study treatment and until 30 days after last dose of SOC chemotherapies and up to 90 days after NIS793, whichever is later.

End point type	Secondary

End point timeframe:

Up to approximately 32 months

End point values	Safety run-in: NIS793 + Gem/Nab-paclitaxel combo	Randomized part (Arm A): NIS793 + Gem/Nab-paclitaxel	Randomized part (Arm B): Placebo + Gem/Nab-paclitaxel	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	21	239	241	
Units: Participants				
Adverse Events (AEs)	21	239	239	
Serious Adverse Events (SAEs)	13	144	110	
Fatal SAEs	0	12	8	
AEs leading to discontinuation	2	46	50	
AEs leading to dose adjustment/interruption	16	205	208	
AEs requiring additional therapy	21	231	227	

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants with dose interruptions and dose reductions of NIS793 in combination with gemcitabine and nab-paclitaxel

End point title	Percentage of participants with dose interruptions and dose reductions of NIS793 in combination with gemcitabine and nab-paclitaxel

End point description:

No dose reductions were allowed for NIS793 in the Randomized part and beyond the first 28 days period of the Safety Run-in part. Increasing the dosing interval from every 2 weeks (Q2W) to every 2 weeks (Q4W) was allowed.
Dose interruption for NIS793 was permitted if adverse drug reaction was suspected to be related to NIS793. If NIS793 was interrupted or delayed for > 8 weeks due to toxicity that was suspected to be related to treatment, study treatment was permanently discontinued.

End point type	Secondary

End point timeframe:

Up to approximately 32 months

End point values	Safety run-in: NIS793 + Gem/Nab-paclitaxel combo	Randomized part (Arm A): NIS793 + Gem/Nab-paclitaxel	Randomized part (Arm B): Placebo + Gem/Nab-paclitaxel	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	21	239	241	
Units: Participants				
With no dose interruption	5	92	82	
With at least one dose interruption	16	147	159	
With no dose reduction	21	237	241	
With at least one dose reduction	0	2	0	

Statistical analyses

No statistical analyses for this end point

Secondary: Dose intensity of NIS793 in combination with gemcitabine and nab-paclitaxel

End point title	Dose intensity of NIS793 in combination with gemcitabine and nab-paclitaxel

End point description:

Dose intensity was computed as the ratio of actual cumulative dose received and actual duration of exposure.

End point type	Secondary

End point timeframe:

Up to approximately 32 months

End point values	Safety run-in: NIS793 + Gem/Nab-paclitaxel combo	Randomized part (Arm A): NIS793 + Gem/Nab-paclitaxel	Randomized part (Arm B): Placebo + Gem/Nab-paclitaxel	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	21	239	241	
Units: mg/cycle				
arithmetic mean (standard deviation)	3669.2 (± 528.07)	3134.1 (± 573.15)	3183.4 (± 593.92)	

Statistical analyses

No statistical analyses for this end point

Secondary: Progression-Free Survival (PFS)

End point title	Progression-Free Survival (PFS)

End point description:

Progression-Free Survival (PFS) was defined as the time from the enrollment (run-in part) or randomization (randomized part) to the date of the first documented disease progression based on local investigator assessment as per RECIST 1.1 or date of death due to any cause, whichever occurs first. PFS was censored if no PFS event was observed before the analysis cut-off date. The censoring date was the date of the last adequate tumor assessment prior to the analysis cut-off.

End point type	Secondary

End point timeframe:

From enrollment (run-in part) or randomization (randomized part) up to disease progression or death, assessed up to approximately 34 months

End point values	Safety run-in: NIS793 + Gem/Nab-paclitaxel combo	Randomized part (Arm A): NIS793 + Gem/Nab-paclitaxel	Randomized part (Arm B): Placebo + Gem/Nab-paclitaxel	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	21	245	245	
Units: Months				
median (confidence interval 95%)	5.4 (3.6 to 7.3)	4.6 (3.7 to 5.4)	5.4 (5.3 to 6.6)	

Statistical analyses

No statistical analyses for this end point

Secondary: Overall Response Rate (ORR)

End point title	Overall Response Rate (ORR)

End point description:

Overall Response Rate (ORR) was defined as the proportion of participants with a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) as per local review. ORR was evaluated according to RECIST 1.1. The BOR was determined from response assessments undertaken while on treatment.

End point type	Secondary

End point timeframe:

Up to approximately 34 months

End point values	Safety run-in: NIS793 + Gem/Nab-paclitaxel combo	Randomized part (Arm A): NIS793 + Gem/Nab-paclitaxel	Randomized part (Arm B): Placebo + Gem/Nab-paclitaxel	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	21	245	245	
Units: Percentage of participants				
number (confidence interval 95%)	19.0 (5.4 to 41.9)	21.6 (16.6 to 27.3)	25.3 (20.0 to 31.2)	

Statistical analyses

No statistical analyses for this end point

Secondary: Disease Control Rate (DCR)

End point title	Disease Control Rate (DCR)

End point description:

Disease Control Rate (DCR) was defined as the proportion of participants with Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR), or Stable Disease (SD) or Non-CR/Non-progressive disease as per local review. DCR was evaluated according to RECIST 1.1.

End point type	Secondary

End point timeframe:

Up to approximately 34 months

End point values	Safety run-in: NIS793 + Gem/Nab-paclitaxel combo	Randomized part (Arm A): NIS793 + Gem/Nab-paclitaxel	Randomized part (Arm B): Placebo + Gem/Nab-paclitaxel	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	21	245	245	
Units: Percentage of participants				
number (confidence interval 95%)	76.2 (52.8 to 91.8)	66.9 (60.7 to 72.8)	72.2 (66.2 to 77.8)	

Statistical analyses

No statistical analyses for this end point

Secondary: Duration of Response (DOR)

End point title	Duration of Response (DOR)

End point description:

Duration of Response (DOR) was defined as the duration of time between the date of first documented response (CR or PR) and the date of first documented progression or death due to any cause.

End point type	Secondary

End point timeframe:

Up to approximately 34 months

End point values	Safety run-in: NIS793 + Gem/Nab-paclitaxel combo	Randomized part (Arm A): NIS793 + Gem/Nab-paclitaxel	Randomized part (Arm B): Placebo + Gem/Nab-paclitaxel	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	53	62	
Units: Months				
number (confidence interval 95%)	8.6 (3.5 to 999)	6.2 (4.7 to 7.4)	5.6 (5.0 to 7.2)	

Statistical analyses

No statistical analyses for this end point

Secondary: Safety run-in part: Trough Concentration (Ctrough) of NIS793 in combination with gemcitabine and nab-paclitaxel

End point title	Safety run-in part: Trough Concentration (Ctrough) of NIS793 in combination with gemcitabine and nab-paclitaxel[5]

End point description:

Venous whole blood samples were collected for activity-based pharmacokinetics characterization. Ctrough was listed and summarized using descriptive statistics.

End point type	Secondary

End point timeframe:

Cycles 1 and 3 Day 1 (0 hour (pre-dose) and 1 hour) and Day 15 (0 hour (pre-dose)), Cycles 2, 4, 6 and 12 Day 1 (0 hour (pre-dose)). 1 cycle = 28 days.

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Endpoint only applicable to Safety run-in: NIS793 + Gem/Nab-paclitaxel combo Arm

End point values	Safety run-in: NIS793 + Gem/Nab-paclitaxel combo			
Subject group type	Reporting group			
Number of subjects analysed	19			
Units: ng/mL				
arithmetic mean (standard deviation)				
Cycle 1 Day 1: 0 hour (pre-dose)	0.00 (± 0.00)			
Cycle 1 Day 1: 1 hour	577000 (± 172000)			
Cycle 1 Day 15: 0 hour (pre-dose)	230000 (± 250000)			
Cycle 2 Day 1: 0 hour (pre-dose)	207000 (± 82400)			
Cycle 3 Day 1: 0 hour (pre-dose)	300000 (± 123000)			
Cycle 3 Day 1: 1 hour	771000 (± 225000)			
Cycle 3 Day 15: 0 hour (pre-dose)	309000 (± 130000)			
Cycle 4 Day 1: 0 hour (pre-dose)	370000 (± 148000)			
Cycle 6 Day 1: 0 hour (pre-dose)	425000 (± 86800)			
Cycle 12 Day 1: 0 hour (pre-dose)	553000 (± 999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Time to Response (TTR)

End point title	Time to Response (TTR)

End point description:

Time to Response (TTR) was defined as the duration of time between the date of enrollment (run-in part) or randomization (randomized part) and the date of first documented response of either CR or PR as per local review, which was subsequently confirmed. TTR was evaluated according to RECIST 1.1. Participants without a confirmed CR or PR were censored at the time of PFS event (i.e., disease progression or death due to any cause) for participants with a PFS event (i.e., disease progression or death due to any cause), or at the date of the last adequate tumor assessment for participants without a PFS event.

End point type	Secondary

End point timeframe:

From enrollment (run-in part) or randomization (randomized part) up to first documented response, assessed up to approximately 34 months

End point values	Safety run-in: NIS793 + Gem/Nab-paclitaxel combo	Randomized part (Arm A): NIS793 + Gem/Nab-paclitaxel	Randomized part (Arm B): Placebo + Gem/Nab-paclitaxel	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	21	245	245	
Units: Months				
number (confidence interval 95%)	999 (999 to 999)	999 (999 to 999)	999 (999 to 999)	

Statistical analyses

No statistical analyses for this end point

Secondary: Safety run-in part: Maximum concentration (Cmax) of NIS793 in combination with gemcitabine and nab-paclitaxel

End point title	Safety run-in part: Maximum concentration (Cmax) of NIS793 in combination with gemcitabine and nab-paclitaxel[6]

End point description:

Venous whole blood samples were collected for activity-based pharmacokinetics characterization. Cmax was listed and summarized using descriptive statistics.

End point type	Secondary

End point timeframe:

Cycles 1 and 3 Day 1: 0 hour (pre-dose) and 1 hour. 1 cycle = 28 days.

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Endpoint only applicable to Safety run-in: NIS793 + Gem/Nab-paclitaxel combo Arm

End point values	Safety run-in: NIS793 + Gem/Nab-paclitaxel combo			
Subject group type	Reporting group			
Number of subjects analysed	19			
Units: ng/mL				
arithmetic mean (standard deviation)				

Cycle 1 Day 1	549000 (± 193000)			
Cycle 3 Day 1	837000 (± 394000)			

Statistical analyses

No statistical analyses for this end point

Secondary: Randomized part (Chinese participants with intensive PK sampling): Trough Concentration (Ctrough) of NIS793 in combination with gemcitabine and nab-paclitaxel

End point title	Randomized part (Chinese participants with intensive PK sampling): Trough Concentration (Ctrough) of NIS793 in combination with gemcitabine and nab-paclitaxel[7]

End point description:

In the randomized part, participants enrolled for treatment in China were assigned to more intensive PK sampling (taken into account the ability of clinical sites to comply with the instructions in the laboratory manual concerning the preparation of serum samples) to assess PK of NIS793 in Chinese participants. Venous whole blood samples were collected for activity-based pharmacokinetics characterization and Ctrough was summarized using descriptive statistics.

End point type	Secondary

End point timeframe:

Cycle 1 Day 15, Cycle 3 Day 1, Cycle 3 Day 15, Cycle 4 Day 1 and Cycle 6 Day 1: 0 hour (pre-dose). 1 cycle = 28 days.

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Endpoint only applicable to Randomized part Arm A

End point values	Randomized part (Arm A): NIS793 + Gem/Nab-paclitaxel			
Subject group type	Reporting group			
Number of subjects analysed	24			
Units: ng/mL				
arithmetic mean (standard deviation)				
Cycle 1 Day 15: 0 hour (pre-dose)	149000 (± 36400)			
Cycle 3 Day 1: 0 hour (pre-dose)	366000 (± 114000)			
Cycle 3 Day 15: 0 hour (pre-dose)	380000 (± 187000)			
Cycle 4 Day 1: 0 hour (pre-dose)	371000 (± 131000)			
Cycle 6 Day 1: 0 hour (pre-dose)	493000 (± 221000)			

Statistical analyses

No statistical analyses for this end point

Secondary: Safety run-in part: Time to reach maximum concentration (Tmax) of NIS793 in combination with gemcitabine and nab-paclitaxel

End point title	Safety run-in part: Time to reach maximum concentration (Tmax) of NIS793 in combination with gemcitabine and nab-paclitaxel[8]

End point description:

Venous whole blood samples were collected for activity-based pharmacokinetics characterization. Tmax was listed and summarized using descriptive statistics.

End point type	Secondary

End point timeframe:

Cycles 1 and 3 Day 1: 0 hour (pre-dose) and 1 hour. 1 cycle = 28 days.

Notes:

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Endpoint only applicable to Safety run-in: NIS793 + Gem/Nab-paclitaxel combo Arm

End point values	Safety run-in: NIS793 + Gem/Nab-paclitaxel combo			
Subject group type	Reporting group			
Number of subjects analysed	19			
Units: Hour				
median (full range (min-max))				
Cycle 1 Day 1	1.12 (0.583 to 5.00)			
Cycle 3 Day 1	0.883 (0.5 to 4.17)			

Statistical analyses

No statistical analyses for this end point

Secondary: Randomized part (Chinese participants with intensive PK sampling): Maximum concentration (Cmax) of NIS793 in combination with gemcitabine and nab-paclitaxel

End point title	Randomized part (Chinese participants with intensive PK sampling): Maximum concentration (Cmax) of NIS793 in combination with gemcitabine and nab-paclitaxel[9]

End point description:

In the randomized part, participants enrolled for treatment in China were assigned to more intensive PK sampling (taken into account the ability of clinical sites to comply with the instructions in the laboratory manual concerning the preparation of serum samples) to assess PK of NIS793 in Chinese participants. Venous whole blood samples were collected for activity-based pharmacokinetics characterization and Cmax was summarized using descriptive statistics.

End point type	Secondary

End point timeframe:

Cycles 1 and 3 Day 1: 0 hour (pre-dose) and 1 hour. 1 cycle = 28 days.

Notes:

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Endpoint only applicable to Randomized part Arm A

End point values	Randomized part (Arm A): NIS793 + Gem/Nab-paclitaxel			
Subject group type	Reporting group			
Number of subjects analysed	24			
Units: ng/mL				
arithmetic mean (standard deviation)				
Cycle 1 Day 1	691000 (± 113000)			
Cycle 3 Day 1	978000 (± 131000)			

Statistical analyses

No statistical analyses for this end point

Secondary: Randomized part (Chinese participants with intensive PK sampling): Time to reach maximum concentration (Tmax) of NIS793 in combination with gemcitabine and nab-paclitaxel

End point title	Randomized part (Chinese participants with intensive PK sampling): Time to reach maximum concentration (Tmax) of NIS793 in combination with gemcitabine and nab-paclitaxel[10]

End point description:

In the randomized part, participants enrolled for treatment in China were assigned to more intensive PK sampling (taken into account the ability of clinical sites to comply with the instructions in the laboratory manual concerning the preparation of serum samples) to assess PK of NIS793 in Chinese participants. Venous whole blood samples were collected for activity-based pharmacokinetics characterization and Tmax was summarized using descriptive statistics.

End point type	Secondary

End point timeframe:

Cycles 1 and 3 Day 1: 0 hour (pre-dose) and 1 hour. 1 cycle = 28 days.

Notes:

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Endpoint only applicable to Randomized part Arm A

End point values	Randomized part (Arm A): NIS793 + Gem/Nab-paclitaxel			
Subject group type	Reporting group			
Number of subjects analysed	24			
Units: Hour				
median (full range (min-max))				
Cycle 1 Day 1	1.52 (0.583 to 7.00)			

Cycle 3 Day 1	3.98 (0.567 to 7.75)			

Statistical analyses

No statistical analyses for this end point

Secondary: Randomized part (Chinese participants with intensive PK sampling): Area under the curve calculated to the end of a dosing interval (tau) at steady-state (AUCtau) of NIS793 in combination with gemcitabine and nab-paclitaxel

End point title	Randomized part (Chinese participants with intensive PK sampling): Area under the curve calculated to the end of a dosing interval (tau) at steady-state (AUCtau) of NIS793 in combination with gemcitabine and nab-paclitaxel[11]

End point description:

In the randomized part, participants enrolled for treatment in China were assigned to more intensive PK sampling (taken into account the ability of clinical sites to comply with the instructions in the laboratory manual concerning the preparation of serum samples) to assess PK of NIS793 in Chinese participants. Venous whole blood samples were collected and AUCtau was summarized using descriptive statistics.

End point type	Secondary

End point timeframe:

Cycles 3 Day 1: 0 hour (pre-dose) and 1 hour. 1 cycle = 28 days.

Notes:

[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Endpoint only applicable to Randomized part Arm A

End point values	Randomized part (Arm A): NIS793 + Gem/Nab-paclitaxel			
Subject group type	Reporting group			
Number of subjects analysed	7			
Units: h*ng/mL				
geometric mean (geometric coefficient of variation)	159000000 (± 25.5)			

Statistical analyses

No statistical analyses for this end point

Secondary: Randomized part (participants without intensive PK sampling): Trough Concentration (Ctrough) of NIS793 in combination with gemcitabine and nab-paclitaxel

End point title	Randomized part (participants without intensive PK sampling): Trough Concentration (Ctrough) of NIS793 in combination with gemcitabine and nab-paclitaxel[12]

End point description:

For participants without intensive PK sampling, venous whole blood samples were collected for activity-

based pharmacokinetics characterization. Ctrough was listed and summarized using descriptive statistics.

End point type	Secondary

End point timeframe:

Cycles 2, 3, 4, 6 and 12 Day 1 (0 hour (pre-dose)). 1 cycle = 28 days.

Notes:

[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Endpoint only applicable to Randomized part Arm A

End point values	Randomized part (Arm A): NIS793 + Gem/Nab-paclitaxel			
Subject group type	Reporting group			
Number of subjects analysed	175			
Units: ng/mL				
arithmetic mean (standard deviation)				
Cycle 2 Day 1: 0 hour (pre-dose)	249000 (± 105000)			
Cycle 3 Day 1: 0 hour (pre-dose)	331000 (± 133000)			
Cycle 4 Day 1: 0 hour (pre-dose)	335000 (± 138000)			
Cycle 6 Day 1: 0 hour (pre-dose)	334000 (± 136000)			
Cycle 12 Day 1: 0 hour (pre-dose)	302000 (± 63600)			

Statistical analyses

No statistical analyses for this end point

Secondary: Randomized part (Chinese participants with intensive PK sampling): Area under the curve from time zero to the last measurable concentration sampling time (AUClast) of NIS793 in combination with gemcitabine and nab-paclitaxel

End point title	Randomized part (Chinese participants with intensive PK sampling): Area under the curve from time zero to the last measurable concentration sampling time (AUClast) of NIS793 in combination with gemcitabine and nab-paclitaxel[13]

End point description:

In the randomized part, participants enrolled for treatment in China were assigned to more intensive PK sampling (taken into account the ability of clinical sites to comply with the instructions in the laboratory manual concerning the preparation of serum samples) to assess PK of NIS793 in Chinese participants. Venous whole blood samples were collected for activity-based pharmacokinetics characterization and AUClast was summarized using descriptive statistics.

End point type	Secondary

End point timeframe:

Cycles 1 Day 1: 0 hour (pre-dose) and 1 hour. 1 cycle = 28 days.

Notes:

[13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Endpoint only applicable to Randomized part Arm A

End point values	Randomized part (Arm A): NIS793 + Gem/Nab-paclitaxel			
Subject group type	Reporting group			
Number of subjects analysed	23			
Units: h*ng/mL				
geometric mean (geometric coefficient of variation)	48900000 (± 104.3)			

Statistical analyses

No statistical analyses for this end point

Secondary: Randomized part (participants without intensive PK sampling): Maximum concentration (Cmax) of NIS793 in combination with gemcitabine and nab-paclitaxel

End point title	Randomized part (participants without intensive PK sampling): Maximum concentration (Cmax) of NIS793 in combination with gemcitabine and nab-paclitaxel[14]

End point description:

For Chinese participants without intensive PK sampling schedule and global participants in the randomized part, for which only sparse PK samples were collected for activity-based pharmacokinetics characterization, Cmax was listed and summarized using descriptive statistics.

End point type	Secondary

End point timeframe:

Cycles 1 and 3: Day 1 (0 hour (pre-dose)). 1 cycle = 28 days.

Notes:

[14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Endpoint only applicable to Randomized part Arm A

End point values	Randomized part (Arm A): NIS793 + Gem/Nab-paclitaxel			
Subject group type	Reporting group			
Number of subjects analysed	175			
Units: ng/mL				
arithmetic mean (standard deviation)				
Cycle 1 Day 1: 0 hour (pre-dose)	625000 (± 185000)			
Cycle 3 Day 1: 0 hour (pre-dose)	807000 (± 228000)			

Statistical analyses

No statistical analyses for this end point

Secondary: Randomized part (participants without intensive PK sampling): Time to reach maximum concentration (Tmax) of NIS793 in combination with gemcitabine and nab-paclitaxel

End point title	Randomized part (participants without intensive PK sampling): Time to reach maximum concentration (Tmax) of NIS793 in combination with gemcitabine and nab-paclitaxel[15]

End point description:

For Chinese participants without intensive PK sampling schedule and global participants in the randomized part, for which only sparse PK samples were collected for activity-based pharmacokinetics characterization, Tmax was listed and summarized using descriptive statistics.

End point type	Secondary

End point timeframe:

Cycles 1 and 3: Day 1 (0 hour (pre-dose)). 1 cycle = 28 days.

Notes:

[15] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Endpoint only applicable to Randomized part Arm A

End point values	Randomized part (Arm A): NIS793 + Gem/Nab-paclitaxel			
Subject group type	Reporting group			
Number of subjects analysed	175			
Units: Hour				
median (full range (min-max))				
Cycle 1 Day 1: 0 hour (pre-dose)	1.08 (0.5 to 5.17)			
Cycle 3 Day 1: 0 hour (pre-dose)	0.833 (0.5 to 2.83)			

Statistical analyses

No statistical analyses for this end point

Secondary: Randomized part: Anti-drug antibodies (ADA) against NIS793 prevalence at baseline

End point title	Randomized part: Anti-drug antibodies (ADA) against NIS793 prevalence at baseline[16]

End point description:

Anti-drug antibodies (ADA) against NIS793 prevalence at baseline refers to the proportion of subjects who have developed antibodies against the drug NIS793 before starting treatment. This is calculated by dividing the number of subjects with ADA-positive samples at baseline by the total number of subjects whose baseline samples were tested for ADA.

End point type	Secondary

End point timeframe:

Baseline

Notes:

[16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Endpoint only applicable to Randomized part Arm A

End point values	Randomized part (Arm A): NIS793 + Gem/Nab-paclitaxel			
Subject group type	Reporting group			
Number of subjects analysed	196			
Units: Participants				
ADA-negative sample at baseline	196			
ADA-positive sample at baseline	0			

Statistical analyses

No statistical analyses for this end point

Secondary: Randomized part: Anti-drug antibodies (ADA) against NIS793 incidence on treatment

End point title	Randomized part: Anti-drug antibodies (ADA) against NIS793 incidence on treatment[17]

End point description:

Anti-drug antibodies (ADA) against NIS793 incidence on treatment refers to the proportion of participants who developed antibodies against the drug NIS793 during the treatment period. This can be categorized into two types:
1) Treatment-induced ADA positive: Participants who were ADA-negative at baseline but became ADA-positive after starting the treatment.
2) Treatment-boosted ADA positive: Participants who were ADA-positive at baseline and showed a significant increase in ADA titer during the treatment.

End point type	Secondary

End point timeframe:

From date of first study drug intake up to approximately 34 months

Notes:

[17] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Endpoint only applicable to Randomized part Arm A

End point values	Randomized part (Arm A): NIS793 + Gem/Nab-paclitaxel			
Subject group type	Reporting group			
Number of subjects analysed	196			
Units: Participants				
Treatment-boosted ADA-positive	0			
Treatment-induced ADA-positive	0			
ADA-negative	196			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse Events (AEs) were collected from first dose of study medication until end of extended follow-up phase (end of study), assessed up to approximately 34 months.

Adverse event reporting additional description:

Consistent with EudraCT disclosure specifications, Novartis has reported under the Serious adverse events field "number of deaths resulting from adverse events" all those deaths, resulting from serious adverse events that are deemed to be causally related to treatment by the investigator.

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	27.0

Reporting groups

Reporting group title	NIS793 2100mg Q2W + Gem/NabP @On-treatment period
Reporting group description:	
NIS793 2100 mg Q2W plus Gemcitabine and Nab-paclitaxel@On-treatment period	
Reporting group title	NIS793 2100mg Q2W + Gem/NabP @Post-treatment period
Reporting group description:	
NIS793 2100 mg Q2W plus Gemcitabine and Nab-paclitaxel@Post treatment period	
Reporting group title	Placebo + Gem/NabP @Post treatment period
Reporting group description:	
Placebo and (Gem + Nab)@Post treatment period	
Reporting group title	NIS793 + Gem/NabP @Post treatment period
Reporting group description:	
NIS793 and (Gem + Nab)@Post treatment period	
Reporting group title	Placebo + Gem/NabP @On-treatment period
Reporting group description:	
Placebo and (Gem + Nab)@On-treatment period	
Reporting group title	NIS793 + Gem/NabP @On-treatment period
Reporting group description:	
NIS793 and (Gem + Nab)@On-treatment period	

Serious adverse events	NIS793 2100mg Q2W + Gem/NabP @On-treatment period	NIS793 2100mg Q2W + Gem/NabP @Post-treatment period	Placebo + Gem/NabP @Post treatment period
Total subjects affected by serious adverse events			
subjects affected / exposed	13 / 21 (61.90%)	2 / 21 (9.52%)	28 / 241 (11.62%)
number of deaths (all causes)	0	19	132
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Oesophageal adenocarcinoma			

subjects affected / exposed	1 / 21 (4.76%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transitional cell carcinoma			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour associated fever			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour haemorrhage			
subjects affected / exposed	1 / 21 (4.76%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Aortic dissection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Deep vein thrombosis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	1 / 241 (0.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Distributive shock			
subjects affected / exposed	1 / 21 (4.76%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embolism			
subjects affected / exposed	0 / 21 (0.00%)	1 / 21 (4.76%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			

subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	1 / 241 (0.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Orthostatic hypotension			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Shock haemorrhagic			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral vein thrombosis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombophlebitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	1 / 21 (4.76%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Death			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Condition aggravated			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthenia			

subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Generalised oedema			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	1 / 241 (0.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Malaise			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema peripheral			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	1 / 21 (4.76%)	0 / 21 (0.00%)	2 / 241 (0.83%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Epistaxis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemoptysis			

subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	1 / 241 (0.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Hiccups			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydrothorax			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	1 / 241 (0.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Interstitial lung disease			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Non-cardiogenic pulmonary oedema			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			

subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	1 / 21 (4.76%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory distress			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Delirium			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Product issues			
Device occlusion			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device dislocation			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stent malfunction			

subjects affected / exposed	1 / 21 (4.76%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Amylase increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood creatinine increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood bilirubin increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	1 / 241 (0.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Troponin increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	1 / 241 (0.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Platelet count decreased			

subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lipase increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Weight decreased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	1 / 241 (0.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
White blood cell count decreased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Anastomotic ulcer			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fractured sacrum			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femur fracture			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic rupture			

subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infusion related reaction			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hip fracture			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal fracture			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular pseudoaneurysm ruptured			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound dehiscence			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute myocardial infarction			
subjects affected / exposed	1 / 21 (4.76%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac arrest			

subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorder			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac valve disease			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiopulmonary failure			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery disease			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular fibrillation			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Palpitations			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			

subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	1 / 241 (0.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Heart failure with preserved ejection fraction			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral haemorrhage			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral infarction			
subjects affected / exposed	1 / 21 (4.76%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dizziness			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	1 / 241 (0.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysstasia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalopathy			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Facial paralysis			

subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	1 / 241 (0.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coma			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolic encephalopathy			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	1 / 241 (0.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhage intracranial			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Motor dysfunction			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	1 / 241 (0.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	1 / 241 (0.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Putamen haemorrhage			

subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neurotoxicity			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuropathy peripheral			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	1 / 241 (0.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Syncope			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Blood loss anaemia			
subjects affected / exposed	0 / 21 (0.00%)	1 / 21 (4.76%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Atypical haemolytic uraemic syndrome			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaemia			
subjects affected / exposed	1 / 21 (4.76%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coagulopathy			

subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Disseminated intravascular coagulation			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukocytosis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile neutropenia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancytopenia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombotic microangiopathy			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Retinal ischaemia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Papilloedema			

subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retinal vasculitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal distension			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain lower			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	1 / 241 (0.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain upper			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ascites			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute abdomen			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			

subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	1 / 241 (0.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal obstruction			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal stenosis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal ulcer			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysphagia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	1 / 241 (0.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric haemorrhage			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric perforation			

subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	1 / 241 (0.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric stenosis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	1 / 21 (4.76%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal toxicity			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal inflammation			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematemesis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhoidal haemorrhage			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematochezia			

subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Impaired gastric emptying			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestinal obstruction			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic enteritis			
subjects affected / exposed	1 / 21 (4.76%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower gastrointestinal haemorrhage			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant ascites			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	1 / 241 (0.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Malignant gastrointestinal obstruction			

subjects affected / exposed	1 / 21 (4.76%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Melaena			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstruction gastric			
subjects affected / exposed	1 / 21 (4.76%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis acute			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Portal hypertensive gastropathy			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal haemorrhage			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	1 / 241 (0.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Small intestinal obstruction			

subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal perforation			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			
subjects affected / exposed	1 / 21 (4.76%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	2 / 21 (9.52%)	0 / 21 (0.00%)	2 / 241 (0.83%)
occurrences causally related to treatment / all	2 / 3	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Autoimmune hepatitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Biliary obstruction			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bile duct stenosis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholangitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis			

subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholangitis acute			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis acute			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gallbladder fistula			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Jaundice cholestatic			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	1 / 241 (0.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Jaundice			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disease			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic function abnormal			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Liver disorder			

subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant biliary obstruction			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Portal vein thrombosis			
subjects affected / exposed	1 / 21 (4.76%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Rash			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Hydronephrosis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	1 / 21 (4.76%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Calculus urinary			
subjects affected / exposed	1 / 21 (4.76%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute kidney injury			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrolithiasis			

subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	1 / 21 (4.76%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscular weakness			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoporotic fracture			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myalgia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain in extremity			
subjects affected / exposed	1 / 21 (4.76%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pathological fracture			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sarcopenia			

subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Abdominal abscess			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	1 / 241 (0.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	1 / 241 (0.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Anal abscess			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacteraemia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	1 / 241 (0.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacterial infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19 pneumonia			

subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholangitis infective			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Biliary tract infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile colitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	1 / 21 (4.76%)	0 / 21 (0.00%)	1 / 241 (0.41%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related sepsis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erysipelas			

subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia sepsis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia urinary tract infection			
subjects affected / exposed	0 / 21 (0.00%)	1 / 21 (4.76%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye infection			
subjects affected / exposed	1 / 21 (4.76%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Giardiasis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	1 / 21 (4.76%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Focal peritonitis			

subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	1 / 241 (0.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Liver abscess			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nail infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal candidiasis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	1 / 241 (0.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oral candidiasis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	1 / 241 (0.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oropharyngitis fungal			

subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	1 / 241 (0.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreas infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	1 / 21 (4.76%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumococcal infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia bacterial			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Penile infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			

subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	2 / 241 (0.83%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Rhinovirus infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinusitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	1 / 21 (4.76%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	1 / 241 (0.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic ketoacidosis			

subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Failure to thrive			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercalcaemia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoalbuminaemia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoglycaemia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			

subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypophosphataemia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malnutrition			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolic acidosis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	NIS793 + Gem/NabP @Post treatment period	Placebo + Gem/NabP @On-treatment period	NIS793 + Gem/NabP @On-treatment period
Total subjects affected by serious adverse events			
subjects affected / exposed	21 / 239 (8.79%)	110 / 241 (45.64%)	144 / 239 (60.25%)
number of deaths (all causes)	135	16	24
number of deaths resulting from adverse events	1	0	3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Oesophageal adenocarcinoma			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transitional cell carcinoma			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour associated fever			

subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour haemorrhage			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	2 / 239 (0.84%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Aortic dissection			
subjects affected / exposed	1 / 239 (0.42%)	0 / 241 (0.00%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Deep vein thrombosis			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Distributive shock			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embolism			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	0 / 239 (0.00%)	4 / 241 (1.66%)	3 / 239 (1.26%)
occurrences causally related to treatment / all	0 / 0	0 / 4	2 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Orthostatic hypotension			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Shock haemorrhagic			

subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral vein thrombosis			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombophlebitis			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	0 / 239 (0.00%)	4 / 241 (1.66%)	3 / 239 (1.26%)
occurrences causally related to treatment / all	0 / 0	2 / 4	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Death			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Condition aggravated			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Asthenia			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	2 / 239 (0.84%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Generalised oedema			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			

subjects affected / exposed	3 / 239 (1.26%)	2 / 241 (0.83%)	6 / 239 (2.51%)
occurrences causally related to treatment / all	0 / 3	0 / 2	1 / 6
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Malaise			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema peripheral			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 239 (0.00%)	11 / 241 (4.56%)	11 / 239 (4.60%)
occurrences causally related to treatment / all	0 / 0	4 / 15	5 / 13
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	2 / 239 (0.84%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Epistaxis			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	3 / 239 (1.26%)
occurrences causally related to treatment / all	0 / 0	0 / 0	3 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemoptysis			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	0 / 239 (0.00%)	3 / 241 (1.24%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	1 / 3	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hiccups			

subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydrothorax			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxia			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Interstitial lung disease			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Non-cardiogenic pulmonary oedema			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	2 / 239 (0.84%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			
subjects affected / exposed	0 / 239 (0.00%)	3 / 241 (1.24%)	2 / 239 (0.84%)
occurrences causally related to treatment / all	0 / 0	3 / 3	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			

subjects affected / exposed	2 / 239 (0.84%)	4 / 241 (1.66%)	4 / 239 (1.67%)
occurrences causally related to treatment / all	0 / 1	2 / 4	1 / 4
deaths causally related to treatment / all	1 / 1	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Respiratory distress			
subjects affected / exposed	1 / 239 (0.42%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Psychiatric disorders			
Delirium			
subjects affected / exposed	0 / 239 (0.00%)	2 / 241 (0.83%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Product issues			
Device occlusion			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	3 / 239 (1.26%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device dislocation			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stent malfunction			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Amylase increased			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood creatinine increased			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood bilirubin increased			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Troponin increased			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Platelet count decreased			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lipase increased			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Weight decreased			

subjects affected / exposed	1 / 239 (0.42%)	0 / 241 (0.00%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
White blood cell count decreased			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Anastomotic ulcer			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	0 / 239 (0.00%)	2 / 241 (0.83%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fractured sacrum			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femur fracture			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic rupture			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infusion related reaction			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hip fracture			

subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	2 / 239 (0.84%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal fracture			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular pseudoaneurysm ruptured			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound dehiscence			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute myocardial infarction			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac arrest			
subjects affected / exposed	1 / 239 (0.42%)	0 / 241 (0.00%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Cardiac disorder			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Cardiac failure			

subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac valve disease			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiopulmonary failure			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Coronary artery disease			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular fibrillation			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Palpitations			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Heart failure with preserved ejection fraction			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebrovascular accident			

subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Cerebral haemorrhage			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral infarction			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	2 / 239 (0.84%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dizziness			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysstasia			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalopathy			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Facial paralysis			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coma			
subjects affected / exposed	1 / 239 (0.42%)	0 / 241 (0.00%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolic encephalopathy			

subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Ischaemic stroke			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	2 / 239 (0.84%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhage intracranial			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Motor dysfunction			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Putamen haemorrhage			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neurotoxicity			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuropathy peripheral			

subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack			
subjects affected / exposed	0 / 239 (0.00%)	2 / 241 (0.83%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Blood loss anaemia			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atypical haemolytic uraemic syndrome			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaemia			
subjects affected / exposed	1 / 239 (0.42%)	3 / 241 (1.24%)	13 / 239 (5.44%)
occurrences causally related to treatment / all	0 / 1	2 / 3	12 / 13
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coagulopathy			
subjects affected / exposed	1 / 239 (0.42%)	0 / 241 (0.00%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Disseminated intravascular coagulation			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenia			

subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukocytosis			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile neutropenia			
subjects affected / exposed	0 / 239 (0.00%)	4 / 241 (1.66%)	4 / 239 (1.67%)
occurrences causally related to treatment / all	0 / 0	3 / 4	4 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancytopenia			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombotic microangiopathy			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Retinal ischaemia			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Papilloedema			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retinal vasculitis			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			

Abdominal distension			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain lower			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain			
subjects affected / exposed	0 / 239 (0.00%)	8 / 241 (3.32%)	3 / 239 (1.26%)
occurrences causally related to treatment / all	0 / 0	0 / 9	1 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain upper			
subjects affected / exposed	1 / 239 (0.42%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ascites			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute abdomen			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 239 (0.00%)	6 / 241 (2.49%)	3 / 239 (1.26%)
occurrences causally related to treatment / all	0 / 0	5 / 6	2 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			

subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal obstruction			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal stenosis			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal ulcer			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	2 / 239 (0.84%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysphagia			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric haemorrhage			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	3 / 239 (1.26%)
occurrences causally related to treatment / all	0 / 0	0 / 1	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric perforation			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric stenosis			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			

subjects affected / exposed	1 / 239 (0.42%)	1 / 241 (0.41%)	4 / 239 (1.67%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal toxicity			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal inflammation			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematemesis			
subjects affected / exposed	0 / 239 (0.00%)	2 / 241 (0.83%)	3 / 239 (1.26%)
occurrences causally related to treatment / all	0 / 0	0 / 3	2 / 3
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Haemorrhoidal haemorrhage			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematochezia			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus			
subjects affected / exposed	1 / 239 (0.42%)	0 / 241 (0.00%)	2 / 239 (0.84%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Impaired gastric emptying			

subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	4 / 239 (1.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestinal obstruction			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic enteritis			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower gastrointestinal haemorrhage			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	2 / 239 (0.84%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Malignant ascites			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant gastrointestinal obstruction			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Melaena			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	3 / 239 (1.26%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstruction gastric			

subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	0 / 239 (0.00%)	2 / 241 (0.83%)	2 / 239 (0.84%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis acute			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	2 / 239 (0.84%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	2 / 239 (0.84%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Portal hypertensive gastropathy			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal haemorrhage			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	1 / 239 (0.42%)	1 / 241 (0.41%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Small intestinal perforation			
subjects affected / exposed	1 / 239 (0.42%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			

subjects affected / exposed	0 / 239 (0.00%)	2 / 241 (0.83%)	8 / 239 (3.35%)
occurrences causally related to treatment / all	0 / 0	0 / 2	2 / 8
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Vomiting			
subjects affected / exposed	0 / 239 (0.00%)	3 / 241 (1.24%)	5 / 239 (2.09%)
occurrences causally related to treatment / all	0 / 0	1 / 3	3 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Autoimmune hepatitis			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Biliary obstruction			
subjects affected / exposed	0 / 239 (0.00%)	5 / 241 (2.07%)	4 / 239 (1.67%)
occurrences causally related to treatment / all	0 / 0	0 / 5	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bile duct stenosis			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholangitis			
subjects affected / exposed	1 / 239 (0.42%)	6 / 241 (2.49%)	7 / 239 (2.93%)
occurrences causally related to treatment / all	0 / 1	2 / 7	1 / 8
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Cholecystitis			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	2 / 239 (0.84%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholangitis acute			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis acute			

subjects affected / exposed	1 / 239 (0.42%)	2 / 241 (0.83%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gallbladder fistula			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Jaundice cholestatic			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	2 / 239 (0.84%)
occurrences causally related to treatment / all	0 / 0	0 / 1	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Jaundice			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disease			
subjects affected / exposed	1 / 239 (0.42%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Hepatic function abnormal			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Liver disorder			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant biliary obstruction			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Portal vein thrombosis			

subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Rash			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	2 / 239 (0.84%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Hydronephrosis			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Calculus urinary			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute kidney injury			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	4 / 239 (1.67%)
occurrences causally related to treatment / all	0 / 0	0 / 1	4 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrolithiasis			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue			

disorders			
Back pain			
subjects affected / exposed	1 / 239 (0.42%)	3 / 241 (1.24%)	4 / 239 (1.67%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscular weakness			
subjects affected / exposed	0 / 239 (0.00%)	2 / 241 (0.83%)	2 / 239 (0.84%)
occurrences causally related to treatment / all	0 / 0	1 / 2	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoporotic fracture			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myalgia			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain in extremity			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pathological fracture			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sarcopenia			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Abdominal abscess			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Abdominal infection			
subjects affected / exposed	1 / 239 (0.42%)	2 / 241 (0.83%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	1 / 1	0 / 2	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal abscess			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	0 / 239 (0.00%)	3 / 241 (1.24%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacteraemia			
subjects affected / exposed	0 / 239 (0.00%)	2 / 241 (0.83%)	2 / 239 (0.84%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacterial infection			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19			
subjects affected / exposed	0 / 239 (0.00%)	2 / 241 (0.83%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19 pneumonia			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholangitis infective			

subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Biliary tract infection			
subjects affected / exposed	0 / 239 (0.00%)	5 / 241 (2.07%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	1 / 5	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile colitis			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Clostridium difficile infection			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	3 / 239 (1.26%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related sepsis			
subjects affected / exposed	1 / 239 (0.42%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Erysipelas			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia infection			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia sepsis			

subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia urinary tract infection			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye infection			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile infection			
subjects affected / exposed	1 / 239 (0.42%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Giardiasis			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Focal peritonitis			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic infection			
subjects affected / exposed	0 / 239 (0.00%)	2 / 241 (0.83%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			

subjects affected / exposed	1 / 239 (0.42%)	2 / 241 (0.83%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 1	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Liver abscess			
subjects affected / exposed	0 / 239 (0.00%)	2 / 241 (0.83%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	0 / 239 (0.00%)	2 / 241 (0.83%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nail infection			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal candidiasis			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oral candidiasis			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oropharyngitis fungal			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreas infection			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			

subjects affected / exposed	0 / 239 (0.00%)	7 / 241 (2.90%)	7 / 239 (2.93%)
occurrences causally related to treatment / all	0 / 0	2 / 8	2 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumococcal infection			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonitis			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	3 / 239 (1.26%)
occurrences causally related to treatment / all	0 / 0	0 / 1	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia bacterial			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Penile infection			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	5 / 239 (2.09%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 2
Sepsis			
subjects affected / exposed	1 / 239 (0.42%)	7 / 241 (2.90%)	5 / 239 (2.09%)
occurrences causally related to treatment / all	0 / 1	3 / 8	1 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhinovirus infection			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			

subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinusitis			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	0 / 239 (0.00%)	2 / 241 (0.83%)	2 / 239 (0.84%)
occurrences causally related to treatment / all	0 / 0	0 / 2	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Urinary tract infection			
subjects affected / exposed	1 / 239 (0.42%)	4 / 241 (1.66%)	4 / 239 (1.67%)
occurrences causally related to treatment / all	0 / 1	2 / 5	2 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	0 / 239 (0.00%)	2 / 241 (0.83%)	4 / 239 (1.67%)
occurrences causally related to treatment / all	0 / 0	1 / 2	4 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			
subjects affected / exposed	0 / 239 (0.00%)	3 / 241 (1.24%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	1 / 3	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic ketoacidosis			
subjects affected / exposed	0 / 239 (0.00%)	2 / 241 (0.83%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 2	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Failure to thrive			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercalcaemia			

subjects affected / exposed	1 / 239 (0.42%)	0 / 241 (0.00%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoalbuminaemia			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	2 / 239 (0.84%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoglycaemia			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 239 (0.00%)	1 / 241 (0.41%)	3 / 239 (1.26%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypophosphataemia			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malnutrition			

subjects affected / exposed	1 / 239 (0.42%)	0 / 241 (0.00%)	0 / 239 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Metabolic acidosis			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	NIS793 2100mg Q2W + Gem/NabP @On-treatment period	NIS793 2100mg Q2W + Gem/NabP @Post-treatment period	Placebo + Gem/NabP @Post treatment period
Total subjects affected by non-serious adverse events			
subjects affected / exposed	21 / 21 (100.00%)	6 / 21 (28.57%)	36 / 241 (14.94%)
Vascular disorders			
Hypertension			
subjects affected / exposed	1 / 21 (4.76%)	0 / 21 (0.00%)	1 / 241 (0.41%)
occurrences (all)	1	0	1
Hypotension			
subjects affected / exposed	2 / 21 (9.52%)	0 / 21 (0.00%)	1 / 241 (0.41%)
occurrences (all)	2	0	2
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	2 / 21 (9.52%)	0 / 21 (0.00%)	4 / 241 (1.66%)
occurrences (all)	3	0	1
Chills			
subjects affected / exposed	1 / 21 (4.76%)	0 / 21 (0.00%)	1 / 241 (0.41%)
occurrences (all)	1	0	1
Pyrexia			
subjects affected / exposed	5 / 21 (23.81%)	1 / 21 (4.76%)	3 / 241 (1.24%)
occurrences (all)	11	1	4
Oedema peripheral			
subjects affected / exposed	4 / 21 (19.05%)	0 / 21 (0.00%)	3 / 241 (1.24%)
occurrences (all)	4	0	1
Mucosal inflammation			

subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	1 / 21 (4.76%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences (all)	1	0	0
Fatigue			
subjects affected / exposed	12 / 21 (57.14%)	0 / 21 (0.00%)	5 / 241 (2.07%)
occurrences (all)	14	0	4
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	2 / 21 (9.52%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences (all)	2	0	0
Dyspnoea			
subjects affected / exposed	1 / 21 (4.76%)	0 / 21 (0.00%)	1 / 241 (0.41%)
occurrences (all)	1	0	1
Epistaxis			
subjects affected / exposed	7 / 21 (33.33%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences (all)	8	0	0
Psychiatric disorders			
Insomnia			
subjects affected / exposed	3 / 21 (14.29%)	0 / 21 (0.00%)	1 / 241 (0.41%)
occurrences (all)	3	0	0
Delirium			
subjects affected / exposed	2 / 21 (9.52%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences (all)	2	0	0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	4 / 21 (19.05%)	0 / 21 (0.00%)	4 / 241 (1.66%)
occurrences (all)	8	0	1
Amylase increased			
subjects affected / exposed	2 / 21 (9.52%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences (all)	5	0	0
Aspartate aminotransferase increased			
subjects affected / exposed	4 / 21 (19.05%)	0 / 21 (0.00%)	5 / 241 (2.07%)
occurrences (all)	5	0	2
Blood alkaline phosphatase increased			

subjects affected / exposed	3 / 21 (14.29%)	0 / 21 (0.00%)	3 / 241 (1.24%)
occurrences (all)	5	0	0
Platelet count decreased			
subjects affected / exposed	4 / 21 (19.05%)	0 / 21 (0.00%)	2 / 241 (0.83%)
occurrences (all)	21	0	2
Lymphocyte count decreased			
subjects affected / exposed	2 / 21 (9.52%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences (all)	3	0	0
Lipase increased			
subjects affected / exposed	3 / 21 (14.29%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences (all)	5	0	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	3 / 21 (14.29%)	0 / 21 (0.00%)	2 / 241 (0.83%)
occurrences (all)	3	0	0
Blood lactate dehydrogenase increased			
subjects affected / exposed	2 / 21 (9.52%)	0 / 21 (0.00%)	2 / 241 (0.83%)
occurrences (all)	9	0	2
Blood bilirubin increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	4 / 241 (1.66%)
occurrences (all)	0	0	2
Neutrophil count decreased			
subjects affected / exposed	3 / 21 (14.29%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences (all)	16	0	0
Weight decreased			
subjects affected / exposed	6 / 21 (28.57%)	1 / 21 (4.76%)	3 / 241 (1.24%)
occurrences (all)	7	1	3
White blood cell count decreased			
subjects affected / exposed	2 / 21 (9.52%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences (all)	8	0	0
White blood cell count increased			
subjects affected / exposed	3 / 21 (14.29%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences (all)	3	0	0
Nervous system disorders			

Dizziness			
subjects affected / exposed	2 / 21 (9.52%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences (all)	2	0	0
Paraesthesia			
subjects affected / exposed	2 / 21 (9.52%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences (all)	3	0	0
Neuropathy peripheral			
subjects affected / exposed	1 / 21 (4.76%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences (all)	2	0	0
Headache			
subjects affected / exposed	4 / 21 (19.05%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences (all)	5	0	0
Dysgeusia			
subjects affected / exposed	2 / 21 (9.52%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences (all)	2	0	0
Peripheral sensory neuropathy			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	1 / 241 (0.41%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	14 / 21 (66.67%)	0 / 21 (0.00%)	10 / 241 (4.15%)
occurrences (all)	19	0	4
Leukopenia			
subjects affected / exposed	2 / 21 (9.52%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences (all)	3	0	0
Thrombocytopenia			
subjects affected / exposed	3 / 21 (14.29%)	0 / 21 (0.00%)	2 / 241 (0.83%)
occurrences (all)	5	0	3
Neutropenia			
subjects affected / exposed	5 / 21 (23.81%)	0 / 21 (0.00%)	1 / 241 (0.41%)
occurrences (all)	19	0	1
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	8 / 21 (38.10%)	1 / 21 (4.76%)	1 / 241 (0.41%)
occurrences (all)	10	1	1
Abdominal distension			

subjects affected / exposed	2 / 21 (9.52%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences (all)	2	0	0
Nausea			
subjects affected / exposed	12 / 21 (57.14%)	0 / 21 (0.00%)	5 / 241 (2.07%)
occurrences (all)	12	0	4
Rectal haemorrhage			
subjects affected / exposed	2 / 21 (9.52%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences (all)	2	0	0
Mouth ulceration			
subjects affected / exposed	2 / 21 (9.52%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences (all)	2	0	0
Haemorrhoids			
subjects affected / exposed	1 / 21 (4.76%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences (all)	1	0	0
Gingival bleeding			
subjects affected / exposed	3 / 21 (14.29%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences (all)	3	0	0
Diarrhoea			
subjects affected / exposed	9 / 21 (42.86%)	1 / 21 (4.76%)	2 / 241 (0.83%)
occurrences (all)	12	1	3
Stomatitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences (all)	0	0	0
Abdominal pain upper			
subjects affected / exposed	1 / 21 (4.76%)	0 / 21 (0.00%)	1 / 241 (0.41%)
occurrences (all)	1	0	0
Constipation			
subjects affected / exposed	7 / 21 (33.33%)	0 / 21 (0.00%)	1 / 241 (0.41%)
occurrences (all)	11	0	1
Vomiting			
subjects affected / exposed	4 / 21 (19.05%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences (all)	6	0	0
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	9 / 21 (42.86%)	0 / 21 (0.00%)	1 / 241 (0.41%)
occurrences (all)	9	0	0

Pruritus			
subjects affected / exposed	2 / 21 (9.52%)	1 / 21 (4.76%)	0 / 241 (0.00%)
occurrences (all)	2	0	0
Rash maculo-papular			
subjects affected / exposed	1 / 21 (4.76%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences (all)	1	0	0
Rash			
subjects affected / exposed	6 / 21 (28.57%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences (all)	8	0	0
Rash papular			
subjects affected / exposed	2 / 21 (9.52%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences (all)	4	0	0
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	2 / 21 (9.52%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences (all)	2	0	0
Haematuria			
subjects affected / exposed	1 / 21 (4.76%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences (all)	2	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences (all)	0	0	0
Joint swelling			
subjects affected / exposed	3 / 21 (14.29%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences (all)	4	0	0
Myalgia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	1 / 241 (0.41%)
occurrences (all)	0	0	1
Pain in extremity			
subjects affected / exposed	1 / 21 (4.76%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences (all)	1	0	0
Back pain			
subjects affected / exposed	4 / 21 (19.05%)	3 / 21 (14.29%)	0 / 241 (0.00%)
occurrences (all)	5	2	0
Infections and infestations			

COVID-19			
subjects affected / exposed	1 / 21 (4.76%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences (all)	1	0	0
Urinary tract infection			
subjects affected / exposed	3 / 21 (14.29%)	0 / 21 (0.00%)	2 / 241 (0.83%)
occurrences (all)	3	0	2
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	8 / 21 (38.10%)	0 / 21 (0.00%)	4 / 241 (1.66%)
occurrences (all)	9	0	2
Hyperglycaemia			
subjects affected / exposed	1 / 21 (4.76%)	0 / 21 (0.00%)	1 / 241 (0.41%)
occurrences (all)	5	0	1
Hypoalbuminaemia			
subjects affected / exposed	1 / 21 (4.76%)	0 / 21 (0.00%)	6 / 241 (2.49%)
occurrences (all)	1	0	2
Hypocalcaemia			
subjects affected / exposed	2 / 21 (9.52%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences (all)	2	0	0
Hypokalaemia			
subjects affected / exposed	4 / 21 (19.05%)	0 / 21 (0.00%)	2 / 241 (0.83%)
occurrences (all)	8	0	3
Hypomagnesaemia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	1 / 241 (0.41%)
occurrences (all)	0	0	1
Iron deficiency			
subjects affected / exposed	4 / 21 (19.05%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences (all)	4	0	0
Hypophosphataemia			
subjects affected / exposed	3 / 21 (14.29%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences (all)	4	0	0
Hyponatraemia			
subjects affected / exposed	0 / 21 (0.00%)	0 / 21 (0.00%)	0 / 241 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	NIS793 + Gem/NabP @Post treatment period	Placebo + Gem/NabP @On-treatment period	NIS793 + Gem/NabP @On-treatment period

Total subjects affected by non-serious adverse events			
subjects affected / exposed	29 / 239 (12.13%)	236 / 241 (97.93%)	228 / 239 (95.40%)
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 239 (0.00%)	13 / 241 (5.39%)	11 / 239 (4.60%)
occurrences (all)	0	17	13
Hypotension			
subjects affected / exposed	0 / 239 (0.00%)	12 / 241 (4.98%)	12 / 239 (5.02%)
occurrences (all)	0	12	15
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 239 (0.00%)	45 / 241 (18.67%)	39 / 239 (16.32%)
occurrences (all)	0	60	54
Chills			
subjects affected / exposed	0 / 239 (0.00%)	13 / 241 (5.39%)	13 / 239 (5.44%)
occurrences (all)	0	14	15
Pyrexia			
subjects affected / exposed	2 / 239 (0.84%)	63 / 241 (26.14%)	75 / 239 (31.38%)
occurrences (all)	2	112	149
Oedema peripheral			
subjects affected / exposed	0 / 239 (0.00%)	66 / 241 (27.39%)	36 / 239 (15.06%)
occurrences (all)	0	79	41
Mucosal inflammation			
subjects affected / exposed	0 / 239 (0.00%)	13 / 241 (5.39%)	11 / 239 (4.60%)
occurrences (all)	0	15	15
Malaise			
subjects affected / exposed	1 / 239 (0.42%)	15 / 241 (6.22%)	21 / 239 (8.79%)
occurrences (all)	0	22	27
Fatigue			
subjects affected / exposed	2 / 239 (0.84%)	78 / 241 (32.37%)	76 / 239 (31.80%)
occurrences (all)	0	96	100
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	0 / 239 (0.00%)	26 / 241 (10.79%)	23 / 239 (9.62%)
occurrences (all)	0	28	25
Dyspnoea			

subjects affected / exposed	1 / 239 (0.42%)	18 / 241 (7.47%)	18 / 239 (7.53%)
occurrences (all)	1	18	22
Epistaxis			
subjects affected / exposed	1 / 239 (0.42%)	20 / 241 (8.30%)	66 / 239 (27.62%)
occurrences (all)	1	26	87
Psychiatric disorders			
Insomnia			
subjects affected / exposed	1 / 239 (0.42%)	26 / 241 (10.79%)	18 / 239 (7.53%)
occurrences (all)	1	26	18
Delirium			
subjects affected / exposed	0 / 239 (0.00%)	2 / 241 (0.83%)	0 / 239 (0.00%)
occurrences (all)	0	2	0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	3 / 239 (1.26%)	63 / 241 (26.14%)	59 / 239 (24.69%)
occurrences (all)	4	113	96
Amylase increased			
subjects affected / exposed	2 / 239 (0.84%)	7 / 241 (2.90%)	9 / 239 (3.77%)
occurrences (all)	1	8	14
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 239 (0.42%)	56 / 241 (23.24%)	54 / 239 (22.59%)
occurrences (all)	3	92	85
Blood alkaline phosphatase increased			
subjects affected / exposed	3 / 239 (1.26%)	21 / 241 (8.71%)	20 / 239 (8.37%)
occurrences (all)	3	26	24
Platelet count decreased			
subjects affected / exposed	3 / 239 (1.26%)	70 / 241 (29.05%)	52 / 239 (21.76%)
occurrences (all)	3	222	127
Lymphocyte count decreased			
subjects affected / exposed	2 / 239 (0.84%)	8 / 241 (3.32%)	17 / 239 (7.11%)
occurrences (all)	3	20	52
Lipase increased			
subjects affected / exposed	1 / 239 (0.42%)	11 / 241 (4.56%)	15 / 239 (6.28%)
occurrences (all)	1	11	22
Gamma-glutamyltransferase increased			

subjects affected / exposed	4 / 239 (1.67%)	25 / 241 (10.37%)	27 / 239 (11.30%)
occurrences (all)	1	28	32
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 239 (0.00%)	7 / 241 (2.90%)	6 / 239 (2.51%)
occurrences (all)	0	11	11
Blood bilirubin increased			
subjects affected / exposed	3 / 239 (1.26%)	14 / 241 (5.81%)	19 / 239 (7.95%)
occurrences (all)	2	22	20
Neutrophil count decreased			
subjects affected / exposed	0 / 239 (0.00%)	78 / 241 (32.37%)	63 / 239 (26.36%)
occurrences (all)	0	278	166
Weight decreased			
subjects affected / exposed	4 / 239 (1.67%)	34 / 241 (14.11%)	44 / 239 (18.41%)
occurrences (all)	3	41	46
White blood cell count decreased			
subjects affected / exposed	1 / 239 (0.42%)	63 / 241 (26.14%)	48 / 239 (20.08%)
occurrences (all)	1	223	140
White blood cell count increased			
subjects affected / exposed	0 / 239 (0.00%)	2 / 241 (0.83%)	3 / 239 (1.26%)
occurrences (all)	0	2	4
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 239 (0.00%)	16 / 241 (6.64%)	15 / 239 (6.28%)
occurrences (all)	0	19	17
Paraesthesia			
subjects affected / exposed	0 / 239 (0.00%)	10 / 241 (4.15%)	10 / 239 (4.18%)
occurrences (all)	0	11	16
Neuropathy peripheral			
subjects affected / exposed	0 / 239 (0.00%)	35 / 241 (14.52%)	31 / 239 (12.97%)
occurrences (all)	0	39	34
Headache			
subjects affected / exposed	0 / 239 (0.00%)	17 / 241 (7.05%)	17 / 239 (7.11%)
occurrences (all)	0	24	19
Dysgeusia			

subjects affected / exposed	0 / 239 (0.00%)	21 / 241 (8.71%)	20 / 239 (8.37%)
occurrences (all)	0	26	22
Peripheral sensory neuropathy			
subjects affected / exposed	0 / 239 (0.00%)	36 / 241 (14.94%)	22 / 239 (9.21%)
occurrences (all)	0	43	26
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	16 / 239 (6.69%)	143 / 241 (59.34%)	165 / 239 (69.04%)
occurrences (all)	2	206	257
Leukopenia			
subjects affected / exposed	0 / 239 (0.00%)	29 / 241 (12.03%)	15 / 239 (6.28%)
occurrences (all)	0	73	44
Thrombocytopenia			
subjects affected / exposed	1 / 239 (0.42%)	32 / 241 (13.28%)	36 / 239 (15.06%)
occurrences (all)	1	84	84
Neutropenia			
subjects affected / exposed	0 / 239 (0.00%)	66 / 241 (27.39%)	49 / 239 (20.50%)
occurrences (all)	0	161	148
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 239 (0.00%)	28 / 241 (11.62%)	25 / 239 (10.46%)
occurrences (all)	0	37	34
Abdominal distension			
subjects affected / exposed	0 / 239 (0.00%)	7 / 241 (2.90%)	9 / 239 (3.77%)
occurrences (all)	0	8	9
Nausea			
subjects affected / exposed	1 / 239 (0.42%)	86 / 241 (35.68%)	89 / 239 (37.24%)
occurrences (all)	0	123	130
Rectal haemorrhage			
subjects affected / exposed	0 / 239 (0.00%)	3 / 241 (1.24%)	8 / 239 (3.35%)
occurrences (all)	0	4	9
Mouth ulceration			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	5 / 239 (2.09%)
occurrences (all)	0	0	5
Haemorrhoids			

subjects affected / exposed	0 / 239 (0.00%)	3 / 241 (1.24%)	14 / 239 (5.86%)
occurrences (all)	0	3	15
Gingival bleeding			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	9 / 239 (3.77%)
occurrences (all)	0	0	11
Diarrhoea			
subjects affected / exposed	2 / 239 (0.84%)	80 / 241 (33.20%)	70 / 239 (29.29%)
occurrences (all)	2	115	111
Stomatitis			
subjects affected / exposed	0 / 239 (0.00%)	8 / 241 (3.32%)	25 / 239 (10.46%)
occurrences (all)	0	9	39
Abdominal pain upper			
subjects affected / exposed	2 / 239 (0.84%)	12 / 241 (4.98%)	13 / 239 (5.44%)
occurrences (all)	2	14	15
Constipation			
subjects affected / exposed	2 / 239 (0.84%)	57 / 241 (23.65%)	47 / 239 (19.67%)
occurrences (all)	2	63	57
Vomiting			
subjects affected / exposed	1 / 239 (0.42%)	53 / 241 (21.99%)	57 / 239 (23.85%)
occurrences (all)	1	78	94
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	0 / 239 (0.00%)	71 / 241 (29.46%)	83 / 239 (34.73%)
occurrences (all)	0	71	83
Pruritus			
subjects affected / exposed	1 / 239 (0.42%)	18 / 241 (7.47%)	28 / 239 (11.72%)
occurrences (all)	1	22	39
Rash maculo-papular			
subjects affected / exposed	0 / 239 (0.00%)	8 / 241 (3.32%)	13 / 239 (5.44%)
occurrences (all)	0	9	15
Rash			
subjects affected / exposed	0 / 239 (0.00%)	45 / 241 (18.67%)	67 / 239 (28.03%)
occurrences (all)	0	53	89
Rash papular			
subjects affected / exposed	0 / 239 (0.00%)	0 / 241 (0.00%)	1 / 239 (0.42%)
occurrences (all)	0	0	1

Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 239 (0.00%)	5 / 241 (2.07%)	4 / 239 (1.67%)
occurrences (all)	0	5	8
Haematuria			
subjects affected / exposed	1 / 239 (0.42%)	4 / 241 (1.66%)	14 / 239 (5.86%)
occurrences (all)	1	4	17
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 239 (0.00%)	18 / 241 (7.47%)	16 / 239 (6.69%)
occurrences (all)	0	23	20
Joint swelling			
subjects affected / exposed	0 / 239 (0.00%)	2 / 241 (0.83%)	1 / 239 (0.42%)
occurrences (all)	0	2	1
Myalgia			
subjects affected / exposed	0 / 239 (0.00%)	17 / 241 (7.05%)	17 / 239 (7.11%)
occurrences (all)	0	20	21
Pain in extremity			
subjects affected / exposed	0 / 239 (0.00%)	15 / 241 (6.22%)	18 / 239 (7.53%)
occurrences (all)	0	21	19
Back pain			
subjects affected / exposed	0 / 239 (0.00%)	19 / 241 (7.88%)	18 / 239 (7.53%)
occurrences (all)	0	21	24
Infections and infestations			
COVID-19			
subjects affected / exposed	0 / 239 (0.00%)	23 / 241 (9.54%)	20 / 239 (8.37%)
occurrences (all)	0	23	20
Urinary tract infection			
subjects affected / exposed	1 / 239 (0.42%)	17 / 241 (7.05%)	28 / 239 (11.72%)
occurrences (all)	1	23	36
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	4 / 239 (1.67%)	63 / 241 (26.14%)	66 / 239 (27.62%)
occurrences (all)	2	77	83
Hyperglycaemia			

subjects affected / exposed	1 / 239 (0.42%)	20 / 241 (8.30%)	12 / 239 (5.02%)
occurrences (all)	1	27	23
Hypoalbuminaemia			
subjects affected / exposed	3 / 239 (1.26%)	24 / 241 (9.96%)	39 / 239 (16.32%)
occurrences (all)	1	30	56
Hypocalcaemia			
subjects affected / exposed	3 / 239 (1.26%)	13 / 241 (5.39%)	30 / 239 (12.55%)
occurrences (all)	1	21	57
Hypokalaemia			
subjects affected / exposed	5 / 239 (2.09%)	24 / 241 (9.96%)	28 / 239 (11.72%)
occurrences (all)	5	36	36
Hypomagnesaemia			
subjects affected / exposed	0 / 239 (0.00%)	9 / 241 (3.73%)	12 / 239 (5.02%)
occurrences (all)	0	13	20
Iron deficiency			
subjects affected / exposed	0 / 239 (0.00%)	4 / 241 (1.66%)	5 / 239 (2.09%)
occurrences (all)	0	4	5
Hypophosphataemia			
subjects affected / exposed	2 / 239 (0.84%)	6 / 241 (2.49%)	35 / 239 (14.64%)
occurrences (all)	2	10	64
Hyponatraemia			
subjects affected / exposed	6 / 239 (2.51%)	14 / 241 (5.81%)	26 / 239 (10.88%)
occurrences (all)	5	21	43

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
08 November 2021	Amendment 1: • Clarification to exclusion criterion #11 to specify where history of HCV with a confirmation of a cure is acceptable for study entry. • Update to allow global or local sourcing of Placebo (i.e., 5% dextrose in water) for NIS793 (randomized part) and update to dosage form of gemcitabine and nab-paclitaxel. • Update to overview of NIS793 with most recent safety data from CNIS793X2101 and CNIS793B12201 studies
13 April 2023	Amendment 2: • In light of the most recently released NIS793 IB Ed 8, this protocol amendment is to update the relevant sections to reflect the changes made in the IB including the schedule of cardiac assessments (echocardiogram/cardiac imaging; ECG and cardiac specific enzymes, Troponin- I and NTproBNP; providing clearer guidance to investigators for collection and reporting of all relevant data in case of a cardiac AE to help with better characterization of a potential cardiac risk) and the most recent updates from NIS793 studies. • Introduction of an interim analysis (IA) for OS that allows the study to stop for lack of efficacy after approximately 50% of the targeted OS events for the final analysis have been documented. The initial study protocol did not foresee for an interim analysis for futility. This was justified by the assumption that data emerging from the ongoing phase 2 study (CNIS793B12201 - daNIS-1) would be available before the randomized part of the daNIS-2 study would be open to recruitment to further inform the study design. Unfortunately, recruitment in daNIS-1 was delayed and no efficacy data were available when enrolment to the randomized part of daNIS-2 was initiated. This newly introduced IA will provide an early opportunity to stop the study in case of insufficient benefit.
18 August 2023	Amendment 3: As of 07-Jul-2023, treatment with NIS793/placebo was stopped based upon the DMC's recommendation due to an unfavorable benefit-risk profile observed in the investigational treatment group (NIS793 + gemcitabine + nab-paclitaxel). This protocol amendment was implemented to reduce the assessment burden for ongoing participants, redefine the study completion date, incorporate updates to protocol per template language, and amend the planned data analysis milestones.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Due to EudraCT system limitations, which EMA is aware of, data using 999 as data points in this record are not an accurate representation of the clinical trial results. Please go to https://www.novctrd.com/#/ for complete trial results

Notes: